about
Vascular Complications of Cancer ChemotherapyRole of CX3CR1 receptor in monocyte/macrophage driven neovascularizationCardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionPhosphatase inhibitors with anti-angiogenic effect in vitroRecapitulating physiological and pathological shear stress and oxygen to model vasculature in health and disease.Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study.A novel clinical indicator using cardiac technetium-99m sestamibi kinetics for evaluating cardiotoxicity in cancer patients treated with multiagent chemotherapy.Targeted agent use in cancer patients at the end of lifeTreatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot studyIncidence of new-onset hypertension in cancer patients: a retrospective cohort study.Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.Effects of a 6-month Tai Chi Qigong program on arterial hemodynamics and functional aerobic capacity in survivors of nasopharyngeal cancer.Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.Life-threatening acute acalculous cholecystitis in a patient with renal cell carcinoma treated by sunitinib: a case report."On-target" cardiac effects of anticancer drugs: lessons from new biology.Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients.Defenders and Challengers of Endothelial Barrier Function.Reducing the toxicity of cancer therapy: recognizing needs, taking action.Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials.
P2860
Q26766269-7DDA16EF-151B-43FD-9870-1AB1136FDCFAQ27313463-DF4F9B57-7FAF-4A9C-9577-AF5E20669D52Q33574045-DAFF6D50-6B44-4DE1-A5C2-C9B96D2E435CQ33588814-258F6E67-2C55-4041-A46D-DB73CE62F2BAQ33600738-F3E0ACD1-4254-43BF-B17D-86C111F9BB5BQ33783068-5CDEE3F1-ED8E-40AB-B2AB-581011E06F5CQ36029249-1C64D9F5-834D-4AF3-A9D8-062E186ADD97Q36404564-699A3702-383A-45D6-B2A8-65D72436B321Q36675356-11CAEC10-A5B7-4672-B28E-9BEEE6B53F88Q37152133-0C50D66D-C0AB-4B96-8DEE-2B54700686A7Q37422797-BD934510-B874-4EAE-9B78-94370FBE0E22Q37656300-6DF0C07F-80C2-486D-A74C-13E0C3551A4FQ37765584-8DEF3F94-C26A-486F-A96B-A1A1B4549CBCQ39178952-3313189D-E379-4A73-957A-4103D5ABA081Q39576475-7BC90536-2300-422B-9CB2-0E013D886115Q42576779-F29D3CB4-68B1-45E3-8DFF-30B97171D344Q42649977-A7012AF3-B1E2-4EFD-8EF0-F6ADB12E298CQ46874972-14258C15-3009-4277-BCC5-EAABBD74F38AQ47408707-1E7E75DF-CFE7-4D86-8707-AEC39EF51E59Q51581622-AF82573F-A2FA-4D51-A2F0-CFF99A7AC636Q54645696-B1BAD5B7-F4B2-4F7E-BC6E-847C16C55091
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vascular complications of selected cancer therapies.
@en
Vascular complications of selected cancer therapies.
@nl
type
label
Vascular complications of selected cancer therapies.
@en
Vascular complications of selected cancer therapies.
@nl
prefLabel
Vascular complications of selected cancer therapies.
@en
Vascular complications of selected cancer therapies.
@nl
P356
P1476
Vascular complications of selected cancer therapies.
@en
P2093
Edward T H Yeh
Iyad N Daher
P304
P356
10.1038/NCPCARDIO1375
P577
2008-10-14T00:00:00Z